Press release
Papillary Thyroid Carcinoma (PTC) Treatment Market to Hit US$ 3.50 Billion by 2035 at 4.6% CAGR, Driven by Targeted Therapies & Precision Oncology; North America Leads with 38% Share
Papillary Thyroid Carcinoma (PTC) Treatment
Growth is strongly influenced by increasing awareness, screening programs, and improved access to advanced oncology services. The shift toward personalized and precision-based therapies is enhancing treatment outcomes and creating new opportunities within the market. North America currently holds the largest market share, driven by robust healthcare infrastructure and strong investment in cancer treatment innovation, while Asia Pacific is emerging as one of the fastest-growing regions, supported by rising incidence rates, improving medical facilities, and expanding adoption of modern cancer care approaches.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/papillary-thyroid-carcinoma-treatment-market?sai-v
Papillary Thyroid Carcinoma (PTC) Treatment focuses on highly effective, targeted therapies and surgical precision to safely remove tumors and prevent recurrence in the most common form of thyroid cancer.
Key Developments
United States
✅ September 2025: U.S. oncology drug developers introduced next-generation targeted therapies for BRAF-mutated papillary thyroid carcinoma, improving precision in advanced or resistant cases.
✅ June 2025: American cancer centers expanded adoption of combination kinase inhibitor regimens to enhance treatment outcomes for patients with aggressive or metastatic PTC.
✅ March 2025: Leading U.S. biotech firms advanced clinical trials for novel immunotherapy agents designed to boost response rates in radioiodine-refractory PTC patients.
Japan
✅ October 2025: Japanese pharmaceutical companies developed improved tyrosine kinase inhibitors with reduced side-effect profiles for long-term management of recurrent PTC.
✅ July 2025: Japan's oncology research institutes introduced genetic profiling platforms to optimize personalized treatment selection for thyroid cancer patients.
✅ April 2025: Japanese hospitals expanded use of minimally invasive surgical technologies and advanced imaging systems to support precision thyroid cancer resection.
Mergers & Acquisitions
United States
✅ May 2025: A U.S.-based oncology therapeutics company acquired a precision-medicine startup specializing in genetic diagnostics for thyroid cancer, strengthening its targeted treatment pipeline.
Japan
✅ February 2025: A Japanese pharmaceutical manufacturer partnered with a domestic biotech company to co-develop next-generation small-molecule therapies for advanced papillary thyroid carcinoma.
✅ January 2025: A Japan-based oncology solutions provider formed a strategic alliance with a U.S. distributor to expand global access to advanced thyroid cancer diagnostic and treatment technologies.
Key Players
Eli Lilly and Company | Teva Pharmaceutical Industries Ltd. | Pfizer Inc. | Varian Medical Systems, Inc. | Siemens Healthineers AG | Accuray Incorporated | Koninklijke Philips N.V. | Elekta AB | GE Healthcare
Key Highlights
• Eli Lilly and Company - Holds 12.6% share of the global oncology and therapeutic solutions market, driven by strong oncology portfolios, targeted therapies, and expanding clinical pipeline.
• Teva Pharmaceutical Industries Ltd. - Accounts for 7.9% market share, supported by its global leadership in generics, oncology injectables, and radiation-supportive therapeutics.
• Pfizer Inc. - Maintains 14.8% share, fueled by innovative oncology drugs, immunotherapy solutions, and strong collaboration in advanced cancer-care technologies.
• Varian Medical Systems, Inc. - Represents 10.3% share, driven by global leadership in radiotherapy equipment, linear accelerators, and advanced oncology treatment planning systems.
• Siemens Healthineers AG - Holds 13.7% share, supported by cutting-edge imaging systems, radiotherapy planning tools, and integrated oncology diagnostics.
• Accuray Incorporated - Maintains 4.2% share, known for precision radiation therapy platforms including CyberKnife and TomoTherapy systems used in advanced tumor targeting.
• Koninklijke Philips N.V. - Accounts for 9.1% share, driven by strong diagnostic imaging, digital oncology solutions, and real-time radiotherapy guidance technologies.
• Elekta AB - Holds 9.8% share, recognized for LINAC systems, stereotactic radiosurgery platforms, and oncology workflow solutions across global cancer centers.
• GE Healthcare - Represents 12.0% share, supported by advanced imaging systems, oncology diagnostics, and AI-driven radiotherapy planning innovations.
Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=papillary-thyroid-carcinoma-treatment-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)
Market Drivers
• Rising global incidence of thyroid cancers, especially papillary thyroid carcinoma, which accounts for nearly 80% of all thyroid malignancies, is driving demand for advanced treatment solutions.
• Increasing adoption of targeted therapies, including tyrosine kinase inhibitors (TKIs) and RET/NTRK inhibitors, is improving treatment outcomes for advanced and metastatic PTC.
• Growing use of precision medicine and molecular diagnostics is enabling earlier detection, personalized therapy selection, and better monitoring of treatment response.
• Expanding awareness of thyroid health, rising screening rates, and improved access to endocrine oncology services are supporting market growth.
• Advancement in minimally invasive surgical techniques and radioiodine therapies is increasing the effectiveness and safety of PTC treatment.
Industry Developments
• October 2025: Drug developers introduced next-generation RET inhibitors with improved efficacy for patients with RAI-refractory papillary thyroid carcinoma.
• August 2025: Pharmaceutical companies launched new combination regimens pairing TKIs with immunotherapy to enhance outcomes for advanced-stage PTC patients.
• June 2025: Clinical research centers expanded trials for NTRK-targeted therapies showing strong responses in mutation-positive PTC cases.
• April 2025: Medical technology innovators deployed AI-based diagnostic platforms that improve accuracy in detecting thyroid nodules and predicting malignancy risk.
Regional Insights
• North America holds a 38% share, driven by "high prevalence of thyroid cancer, strong adoption of targeted therapies, advanced healthcare systems, and ongoing clinical research activity."
• Europe accounts for a 30% share, supported by "growing access to molecular diagnostics, expanding oncology treatment centers, and rising demand for personalized thyroid cancer therapies."
• Asia Pacific represents a 25% share, fueled by "increasing thyroid disorder cases, improving healthcare infrastructure, and rising adoption of advanced surgical and targeted treatment technologies."
• Latin America holds a 4% share, driven by "rising cancer awareness, development of oncology facilities, and higher use of radioiodine-based treatment."
• Middle East & Africa account for a 3% share, supported by "growing access to specialized cancer care and adoption of modern diagnostic and therapeutic options."
Key Segments:
➥ By Treatment
Surgery remains a key treatment option, particularly for patients with large thyroid nodules, aggressive malignancies, or conditions unresponsive to medication, offering definitive removal of diseased tissue. Iodine therapy continues to be widely adopted for its high effectiveness in treating hyperthyroidism and thyroid cancer by selectively destroying overactive or malignant thyroid cells. Thyroxin treatment serves as the most common long-term therapy, restoring hormonal balance in patients with hypothyroidism and post-thyroidectomy hormone deficiencies. External radiotherapy is utilized for advanced or metastatic thyroid conditions, providing targeted destruction of cancerous cells while minimizing damage to surrounding tissues. Chemotherapy is reserved for rare, aggressive, or treatment-resistant thyroid cancer types where systemic therapy is required. Other treatments include targeted therapies, biologics, and supportive care approaches tailored to patient-specific disease profiles and clinical needs.
➥ By End-User
Hospitals remain the primary treatment centers due to their advanced diagnostic infrastructure, availability of specialized endocrinologists and oncologists, and capability to perform complex surgical and radiological procedures. Ambulatory centers are increasingly preferred for routine follow-ups, minor procedures, and outpatient therapies, offering cost-effective and convenient care. Retail pharmacies play a vital role in dispensing thyroxin, supportive medications, and long-term treatment prescriptions, making them essential for chronic disease management. Hospital pharmacies ensure continuous supply of specialized medications, radiopharmaceuticals, and perioperative drugs used in inpatient thyroid care. Oncology centers offer specialized treatment for advanced thyroid cancers, integrating chemotherapy, radiotherapy, and targeted therapies under expert clinical guidance.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/papillary-thyroid-carcinoma-treatment-market?sai-v
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Papillary Thyroid Carcinoma (PTC) Treatment Market to Hit US$ 3.50 Billion by 2035 at 4.6% CAGR, Driven by Targeted Therapies & Precision Oncology; North America Leads with 38% Share here
News-ID: 4289504 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Physician Dispensed Cosmeceuticals Market to Reach US$ 69.84 Billion by 2033 at …
The physician dispensed cosmeceuticals market reached US$ 36.55 billion in 2024 and is projected to reach US$ 69.84 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025-2033, according to the DataM Intelligence report. Market growth is primarily driven by increasing consumer preference for clinically proven, dermatologist-recommended skincare products that address concerns such as aging, acne, hyperpigmentation, and sensitive skin. Rising awareness of skin health, coupled…
Point-of-Care Ultrasound Market to Reach US$ 4.60 Billion by 2033 at 8.8% CAGR; …
The point-of-care ultrasound (POCUS) market reached US$ 1.99 billion in 2023, increased to US$ 2.16 billion in 2024, and is projected to reach US$ 4.60 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. Market expansion is driven by the growing need for rapid, accurate, and bedside diagnostic imaging across emergency care, critical care, anesthesiology, cardiology, and primary care settings. The shift toward decentralized healthcare…
Procurement as a Service Market to Reach US$ 16.74 Billion by 2033 at 10.4% CAGR …
The global Procurement as a Service (PaaS) market reached US$ 6.30 billion in 2023, increased to US$ 6.87 billion in 2024, and is expected to reach US$ 16.74 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033. Market growth is driven by rising demand from manufacturing, automotive, electronics, and healthcare industries for scalable, cost-efficient procurement solutions. Organizations are increasingly adopting PaaS to streamline sourcing, supplier…
Precision Potentiometers Market Set for Strong Growth to USD 2.30 Billion by 203 …
The Global Precision Potentiometers Market reached USD 1.40 billion in 2023 and is expected to reach USD 2.30 billion by 2031, growing with a CAGR of 6.3% during the forecast period 2024-2031.
Market growth is driven by rising demand for high-accuracy sensing in electronics, automotive electronics, and industrial automation. Advancements in miniaturization, integration with IoT devices, expanding applications in aerospace and medical devices, and growing emphasis on precision instrumentation are further…
More Releases for PTC
PTC Heating Ceramic Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global PTC Heating Ceramic Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The PTC (Positive Temperature Coefficient) heating ceramic market is experiencing notable growth due to its extensive use in various applications, including consumer electronics, automotive,…
PTC Heaters Market Size 2024 to 2031.
Market Overview and Report Coverage
PTC heaters, or Positive Temperature Coefficient heaters, are self-regulating heating elements used in various applications like automotive, appliances, and industrial equipment. They provide efficient and consistent heating by automatically adjusting their power output based on temperature changes.
The future outlook for the PTC heaters market is bright, with a projected CAGR of 19.40% during the forecasted period. This growth can be attributed to the increasing…
Ceramic PTC and Polymer PTC Market to Witness Huge Growth by 2029 | Polytronics, …
The Ceramic PTC and Polymer PTC report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research.
The Ceramic PTC and Polymer PTC…
Rapid Sheet Metal Introduces “SolidQuote PTC Creo”
Free & simple instant sheet metal quoting add-in for PTC Creo users
Nashua, NH – Rapid Sheet Metal, a dedicated rapid prototype sheet metal shop, is excited to announce the release of SolidQuote for PTC Creo. SolidQuote allows product development engineers to quote and order sheet metal parts and assemblies instantly. Recognizing many mechanical engineers and designers don’t have the time to sit around waiting for quotes, Rapid has developed…
Pipeline Technology Conference, ptc moves to Berlin
Having grown up as part of HANNOVER MESSE, Europe’s leading pipeline conference and trade show, Pipeline Technology Conference (ptc), will move to the capital Berlin next year.
The ptc has grown steadily over the years and, in addition to the conference itself and the accompanying exhibition, it is now also directly followed by several special workshops and in-depth seminars. International participants from over 30 different countries use the opportunity to…
euroscript to resell PTC leading PLM solutions
New solution offering to drive shortened project cycles and cost savings
Bertrange, 29 July 2009 – euroscript International, a leader in providing global solutions in content lifecycle management, announced today that it has joined the PTC (Nasdaq: PMTC) Advantage Network Program as Enterprise Solution Provider – Gold. The partnership is especially significant for manufacturers who already benefit from euroscript’s solutions and services in the field of technical authoring, documentation, translation and…
